SOTACOR

This brand name is authorized in Australia, Brazil, Finland, Japan, New Zealand, United Kingdom

Active ingredients

The drug SOTACOR contains one active pharmaceutical ingredient (API):

1 Sotalol UNII HEC37C70XX - SOTALOL HYDROCHLORIDE

D,l-sotalol is a non-selective hydrophilic β-adrenergic receptor blocking agent, devoid of intrinsic sympathomimetic activity or membrane stabilizing activity. Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. Read about Sotalol

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SOTACOR Tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C07AA07	Sotalol	C Cardiovascular system → C07 Beta blocking agents → C07A Beta blocking agents → C07AA Beta blocking agents, non-selective
Discover more medicines within C07AA07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2043M, 8398B
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 505105501118317, 505105502114315
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 027938
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 184856
Country: JP	医薬品医療機器総合機構	Identifier(s): 2129013F1026, 2129013F2022
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 2235, 2236, 2237